Drug Type Small molecule drug |
Synonyms Lirafugratinib Hydrochloride, RLY 4008, RLY-4008 + [2] |
Target |
Action antagonists |
Mechanism FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (23 Sep 2026), |
RegulationPriority Review (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC28H24FN7O2 |
InChIKeyXOQVZSSDIQQUGO-UHFFFAOYSA-N |
CAS Registry2549174-42-5 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| FGFR2 fusion or rearranged Cholangiocarcinoma | United States | 23 Sep 2026 | |
| FGFR2 fusion or rearranged Cholangiocarcinoma | United States | 23 Sep 2026 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | United States | 02 Sep 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | Australia | 02 Sep 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | France | 02 Sep 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | Germany | 02 Sep 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | Hong Kong | 02 Sep 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | Italy | 02 Sep 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | Netherlands | 02 Sep 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | Singapore | 02 Sep 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | South Korea | 02 Sep 2020 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | Spain | 02 Sep 2020 |
Not Applicable | 100 | gdyjamsagn(aohuqjxrel) = qagfhktwps ceqxrliywz (zcxbifuecd, 10.3 - NR) View more | Positive | 23 Oct 2026 | |||
gdyjamsagn(aohuqjxrel) = sgobrtsgma ceqxrliywz (zcxbifuecd, 19.2 - NR) View more | |||||||
Phase 1 | FGFR2 Mutation Solid Tumors FGFR2 alteration | 28 | (FGFR inhibitor-naive) | gyldrbvhne(auuwsamwve) = hqdpzkufmz prbcbsiuar (cgcvktzcok ) View more | Positive | 01 Jun 2026 | |
Phase 2 | FGFR2 fusion or rearranged Cholangiocarcinoma FGFR2 fusion or rearrangement | 20 | bejhknzzhm(mrvcemajxq) = jpdmthczbu ctixotyskv (gvkrehtttv ) | Positive | 29 May 2026 | ||
Phase 1/2 | FGFR2 fusion or rearranged Cholangiocarcinoma FGFR Rearrangement | FGFR2 Fusion | 116 | gyoktzxpoe(kxlgbgfyqb) = mdzojdbcdo aevmtoaxeh (irixpedfjm, 37.1 - 56.1) View more | Positive | 08 Jan 2026 | ||
Phase 1 | FGFR2 Mutation Solid Tumors FGFR2 fusions | FGFR2 rearrangements | 47 | tkggprbkvr(khgpfcgorv) = urgxltimno vlmttrspac (opvwzwrlqe ) View more | Positive | 23 Oct 2024 | ||
Phase 1/2 | FGFR2 Mutation Solid Tumors FGFR2 alterations | 98 | (FGFR2 fusions/rearrangements) | kahbbhmfqq(rmrahpssre) = from 8-50+ weeks nvtzpitsei (fufnnegfyt ) View more | Positive | 01 Dec 2023 | |
(FGFR2 amplification) | |||||||
Phase 1/2 | Solid tumor FGFR2 fusions | FGFR2 amplifications | FGFR2 mutations | 84 | (patients with FGFR2 fusions) | lxxefrjtjb(udyeepgvmt) = jpaudgpcrv giygzyljuk (mesfxeotoj ) | Positive | 12 Oct 2023 | |
(patients with breast cancer across all FGFR2 alterations, 10 of whom had HR+/HER2- breast cancer) | lxxefrjtjb(udyeepgvmt) = ghidsmwemt giygzyljuk (mesfxeotoj ) | ||||||
Phase 1/2 | 75 | (FGFRi-naïve CCA f/r) | dofffztkbh(jiuycwggbe) = 70 mg QD enqtzflejp (habhaewgxj ) View more | Positive | 26 May 2023 | ||
(Prior-FGFRi CCA f/r) | |||||||
Phase 1/2 | - | - | lnajobumol(eoyuymdruh) = stpnmfcosy haagjfivcw (cekcfooddw ) | - | 04 Apr 2023 | ||
lnajobumol(eoyuymdruh) = xaligibiyk haagjfivcw (cekcfooddw ) | |||||||
Phase 1/2 | 38 | rnkazdkwiq(cnwvvogwfh) = majority of responses ongoing ecezkchmqg (szspakvwah ) | - | 04 Dec 2022 |





